Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Vomiting 27Nausea 17Neoplasms 12Breast Neoplasms 4Multiple Myeloma 2Lymphoma 2Leukemia 2Hematologic Neoplasms 2Breast Neoplasms, Male 2Weight Loss 1Solid Tumors 1Sarcoma 1Rectal Neoplasms 1Pain 1Nausea With Vomiting Chemotherapy-Induced 1Melanoma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Inflammatory Breast Neoplasms 1Hematologic Diseases 1Glioma 1Genital Neoplasms, Female 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Anorexia 1

Interventions

Ipilimumab 114pembrolizumab 95Nivolumab 91aldesleukin 86Interleukin-2 57Cyclophosphamide 54Dacarbazine 52Vemurafenib 39trametinib 37Temozolomide 37incomplete Freund's adjuvant 35fludarabine phosphate 35sargramostim 32dabrafenib 32fludarabine 26Bevacizumab 26Paclitaxel 22MART-1 Antigen 21Granulocyte-Macrophage Colony-Stimulating Factor 21montanide ISA 51 20Interferon-alpha 20Cisplatin 20Carboplatin 19Sorafenib 18Introns 17Biopsy 17cobimetinib 16Radiosurgery 16atezolizumab 15Radiotherapy 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Melanoma × Palonosetron × Clear all
NCT00412425 2012-05-04

Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting

M.D. Anderson Cancer Center

Phase 1/2 Completed
30 enrolled 4 charts
Dermatologic

Anorexia, Melanoma, Nausea, Vomiting, Weight Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡